Tavapadon (Juvmo – Abbvie), an oral nonergot partial dopamine agonist, has been approved by the FDA for treatment of Parkinson's disease (PD).
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: